89bio Positive Ph2b Pegozafermin NASH Data; Novartis Discontinues Inclisiran UK Primary Prevention Trial; Novo Nordisk Partners with Dewpoint Therapeutics; Evkeeza Receives Pediatric Approval
A series of cardiometabolic-related news items have been observed from 89bio, Novartis, Dewpoint Therapeutics, and Regeneron. Below, FENIX provides highlights and insights into the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.